Molecular Targeting Technologies, Inc. (MTTI) is a Pennsylvania-based
biotechnology company primarily focused on the development of small molecules for
the molecular imaging of cardiovascular diseases and cancer. We have licensed a
number of proprietary molecules that allow us to target glioma and prostate cancers as
well as Alzheimer’s diseases. MTTI is also advancing therapeutic human monoclonal
antibody for Rabies post-exposure treatment and Fusion Protein Technology for
development of a Botulinum neurotoxin vaccine. In addition, MTTI is building a research
reagents business for an immediate revenue stream and currently offers a range of
innovative fluorescence based products and bead based products for in vitro and in vivo
research applications.
Mission:
Molecular Targeting Technologies, Inc. is committed to being a leading biotechnology
company dedicated to translating novel technologies into tomorrow's medicine.
Molecular Targeting Technologies Inc.